Yestar Healthcare Holdings Company Limited
巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

SUPPLEMENTAL ANNOUNCEMENT
DISCLOSEABLE TRANSACTIONS IN RELATION TO ACQUISITIONS OF EQUIPMENT FOR THE PRODUCTION OF ADVANCED MATERIALS

Reference is made to the announcement of Yestar Healthcare Holdings Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 6 February 2026 in respect of the discloseable transactions in relation to the Acquisitions (the "**Announcement**"). Unless otherwise defined, capitalised terms used in this supplemental announcement shall have the same meanings as those defined in the Announcement.

The board (the "**Board**") of directors (the "**Directors**") of the Company would like to provide further information in relation to the Acquisitions to the Shareholders and potential investors of the Company.

BASIS OF THE CONSIDERATION

As disclosed in the Announcement, the consideration payable by the Purchaser pursuant to the First Agreement and the Second Agreement is on normal commercial terms and is agreed after arm's length negotiation principally with reference to the market price of the Production Equipment and the Main Equipment, respectively.

Pursuant to the valuation (the "**Valuation**") of the Production Equipment and the Main Equipment (the "**Equipment**") conducted by the independent valuer, Beijing Yingyue Asset Appraisal Co., Ltd.* (北京贏越資產評估有限公司) (the "**Valuer**"), it was confirmed that the consideration for the Production Equipment and the Main Equipment (the "**Equipment**") is in line with the market value of such equipment.

Valuation Approach

The Valuer considered the three generally accepted approaches in the course of the Valuation, namely (i) the cost approach, which determines the value of the subject asset by considering the cost to reconstruct or replace it, deducting appropriate depreciation to arrive at the asset's value; (ii) the market approach, which evaluates the current fair market value of the subject asset by reference to comparable market transactions; and (iii) the income approach, which determines value by capitalising or discounting the expected future income stream from the subject asset.

As the subject asset comprises custom-made imported specialised equipment and materials, its secondary market is not a public market with active trading, and transaction data is difficult to obtain. Therefore, the Valuer considers that the market approach is not feasible for valuing the subject asset and did not adopt the market approach in the Valuation.

Given that (i) the equipment and materials within the scope of this valuation are used in the production of advanced materials, whose future operating income is heavily influenced by macroeconomic developments and market consumption demand; and (ii) currently, the asset group is only at the stage of asset acquisition, and the realisation of its expected future income is subject to significant uncertainty, the Valuer considers that the cost approach is more reliable than the income approach, as it objectively reflects the current market value of the asset from the perspective of asset construction. Accordingly, the Valuer adopted the cost approach for the Valuation.

Key Valuation Inputs

In adopting the cost approach, the Valuer first estimated the replacement full cost (excluding VAT) of the assets as at the valuation benchmark date of 15 October 2025 (the "**Valuation Benchmark Date**"), through verifying recent market purchase prices from the Vendor, using FOB prices as the base and adding reasonable costs such as ocean freight, overseas transport insurance, domestic handling fees, foundation costs, installation and commissioning fees, bank finance charges, trade handling fees, and capital costs, then deducted the estimated replacement full cost by depreciation, which was essentially physical deterioration given the assets are brand-new and unused with no functional or economic obsolescence, to arrive at the appraised value.

Valuation Conclusion

Based on the cost approach, the Equipment was appraised by the Valuer at approximately RMB55,880,000, equivalent to approximately US$7,871,000, as the Valuation Benchmark Date.

Valuation Assumptions

The Valuer adopted the following key assumptions in the Valuation:

(a) basic assumptions including transaction assumption and open market assumption;

(b) general assumptions including:

(i) there are no material changes to laws, regulations and policies applicable to the Vendor's industry;

(ii) there are no unforeseen macroeconomic shifts beyond public knowledge;

(iii) bank lending rates and foreign exchange fluctuations remain within reasonable bounds;

(iv) there are no significant tax regime changes other than those publicly announced;

(v) there are no major force majeure events or other unforeseeable adverse factors;

(vi) there are no material changes to the Vendor's accounting policies or methods after the Valuation Benchmark Date; and

(vii) there are no fundamental changes to the Purchaser's operating model;

(c) special assumptions including:

(i) all necessary licences, permits and approvals are obtainable or renewable as required from relevant authorities or organisations; and

(ii) there has been full disclosure of all material factors that may impact value between the Valuer and the Vendor;

(d) other assumptions including:

(i) all applicable national laws, administrative, industry, financial and tax policies remain stable and has been or will be fully complied with by the Vendor;

(ii) there are no material disruptions to global financial conditions, the national macroeconomic environment or regional political, economic and social stability; and

(iii) there are no significant changes to interest rates, exchange rates, tax bases or rates, or policy levies.

Validity Period

The valuation conclusion remains valid for a period of one year from the Valuation Benchmark Date of 15 October 2025 to 14 October 2026, after which a fresh asset valuation will be required.

The Board's View

Given the above, the Board considers that the valuation approach, the key valuation inputs and the key assumptions adopted by the Valuer in the Valuation are fair and reasonable.

Based on the Valuation, the Board considers that the consideration for the Production Equipment and the Main Equipment is in line with the market value of such equipment, is on normal commercial terms, is fair and reasonable and in the interests of the Group and the Shareholders as a whole.

DELIVERY SCHEDULE

As disclosed in the Announcement, the Production Equipment and the Main Equipment shall be delivered within 4 months from the date of receipt of payment, respectively (the "**Delivery Period**").

The Board considers that the Delivery Period is fair and reasonable for the following reasons:

(i) the Production Equipment and the Main Equipment are bulky and complicated, requiring significant time for disassembly and full payment of purchase price prior to shipment; and

(ii) the Production Equipment and the Main Equipment are supplied from the Netherlands and therefore an export licence from the Dutch government is required, involving additional processing time.

Therefore, taking into account the time required for disassembly, export licence application, as well as logistics and delivery from the Netherlands, the Board considers that the Delivery Period is fair and reasonable and in the interest of the Group and the Shareholders as a whole.

To safeguard the Group's interests, the Group has been and will continue to closely monitoring the delivery progress of the Equipment, including but not limited to maintaining close communication with the Vendor, requesting regular progress update from the Vendor on the approval status of the export licence from the Dutch government and tracking shipment with the shipping company or logistics provider.

INFORMATION OF THE VENDOR

As at the date of this announcement, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, the ultimate beneficial owner of the Vendor is Mr. Ho Tony (何震東).

To the best of the Director's knowledge, information and belief having made all reasonable enquiries, the Vendor and Mr. Ho Tony (何震東) are Independent Third Parties

By Order of the Board
Yestar Healthcare Holdings Company Limited
Wang Chunlai
CEO and executive Director

Hong Kong, 13 March 2026

As at the date of this announcement, the executive Directors are Mr. Wang Chunlai, Mr. Qiao Jinrong and Ms. Liao Changxiang; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.

For the purpose of this announcement, unless otherwise indicated, conversion of US$ into RMB is calculated at the approximate exchange rate of US$1.00 to RMB7.0995. This exchange rate is for illustration purpose only and does not constitute a representation that any amounts have been, could have been, or may be exchanged at this or any other rate at all.